Evidence map›Paper›PMID 28929385›Full record

ReviewNeurotoxicity research2018

L-Serine: a Naturally-Occurring Amino Acid with Therapeutic Potential.

J S Metcalf, R A Dunlop, J T Powell, S A Banack, P A Cox

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in Neurotoxicity research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03580616 (Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis), which is not on this map. Cited by 45 papers.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03580616 phase2terminatednot on this map

Tolerability and Efficacy of L-Serine in Patients With Amyotrophic Lateral Sclerosis: A Phase IIa Study

TypeinterventionalSponsorElijah W. StommelRan2018 to 2022Enrolled43ConditionsAmyotrophic Lateral Sclerosis (ALS)ArmsL-Serine
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 89 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Metabolic Signatures of FourMetabolites · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

J S MetcalfBrain Chemistry Labs, The Institute for Ethnomedicine, Jackson, 83001, WY, USA.
R A DunlopBrain Chemistry Labs, The Institute for Ethnomedicine, Jackson, 83001, WY, USA.
J T PowellBrain Chemistry Labs, The Institute for Ethnomedicine, Jackson, 83001, WY, USA.
S A BanackBrain Chemistry Labs, The Institute for Ethnomedicine, Jackson, 83001, WY, USA.
P A CoxBrain Chemistry Labs, The Institute for Ethnomedicine, Jackson, 83001, WY, USA. paul@ethnomedicine.org.
Institute for EthnoMedicine · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In human neuroblastoma cell cultures, non-human primates and human beings, L-serine is neuroprotective, acting through a variety of biochemical and molecular mechanisms. Although L-serine is generally classified as a non-essential amino acid, it is probably more appropriate to term it as a "conditional non-essential amino acid" since, under certain circumstances, vertebrates cannot synthesize it in sufficient quantities to meet necessary cellular demands. L-serine is biosynthesized in the mammalian central nervous system from 3-phosphoglycerate and serves as a precursor for the synthesis of the amino acids glycine and cysteine. Physiologically, it has a variety of roles, perhaps most importantly as a phosphorylation site in proteins. Mutations in the metabolic enzymes that synthesize L-serine have been implicated in various human diseases. Dosing of animals with L-serine and human clinical trials investigating the therapeutic effects of L-serine support the FDA's determination that L-serine is generally regarded as safe (GRAS); it also appears to be neuroprotective. We here consider the role of L-serine in neurological disorders and its potential as a therapeutic agent.

Indexed as

AnimalsHumansNervous System DiseasesNeuroprotective AgentsSerineNeuroprotective AgentsSerineALSAlzheimer’s DiseaseL-serineNeurodegenerationNeuroprotectionTherapy

Identifiers

PMID28929385
OpenAlexW2755661463

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.